Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer

Oral Oncol. 2022 Nov:134:106085. doi: 10.1016/j.oraloncology.2022.106085. Epub 2022 Sep 18.
No abstract available

Keywords: Cabazitaxel; Docetaxel; Head and neck cancer; Long term; Palliative; Second Line.

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Docetaxel / therapeutic use
  • Head and Neck Neoplasms* / drug therapy
  • Humans
  • Neoplasm Recurrence, Local* / drug therapy
  • Taxoids / therapeutic use
  • Treatment Outcome

Substances

  • Taxoids
  • Docetaxel
  • cabazitaxel